On October 6, 2022 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical data from its dual combination COM701/nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place between 10-12 November 2022, Boston, MA (Press release, Compugen, OCT 6, 2022, View Source [SID1234621808]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral presentation details:
Title: COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
Abstract Number: 659
Session Title: Clinical Development of Novel Checkpoint Inhibitors
Session Date Thursday, November 10, 2022, 6:45pm ET
Title: PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion
Abstract Number: 504
Session Title: Next Generation Checkpoint Blockade: Mechanisms of Action
Session Date: Friday, November 11, 2022, 5:20pm ET
Compugen’s presentations will be available on the publications section of Compugen’s website, www.cgen.com following presentation.